2022 World Conference on Lung Cancer (ePosters)-EP08.02-086. Randomized Double-blind Placebo-controlled trial of Nicotinamide and EGFR-TKIs for EGFR-mutated Lung Adenocarcinoma

EP08.02-086. Randomized Double-blind Placebo-controlled trial of Nicotinamide and EGFR-TKIs for EGFR-mutated Lung Adenocarcinoma

Back to course

Pdf Summary

A randomized double-blind placebo-controlled trial was conducted to evaluate the effects of nicotinamide, a form of vitamin B3, in combination with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for the treatment of lung adenocarcinoma with EGFR mutations. The study aimed to assess progression-free survival (PFS) and overall survival (OS) in patients receiving nicotinamide compared to those receiving placebo.<br /><br />RUNX3, a tumor suppressor gene, is known to be downregulated in lung adenocarcinoma and is associated with poor clinical outcomes. Nicotinamide has been shown to reactivate the epigenetically silenced tumor suppressor RUNX3 in cancer cells.<br /><br />A total of 110 patients with stage IV lung cancer and EGFR mutations were enrolled in the study and randomized into the nicotinamide or placebo groups. The mean age of the patients was 68.5 years, with a majority being female (63.6%) and never-smokers (76.4%). The patients were treated with EGFR-TKIs along with either nicotinamide or placebo for up to 2 years.<br /><br />The results showed that the addition of nicotinamide to EGFR-TKIs resulted in numerically longer PFS and OS compared to the use of EGFR-TKIs alone. The median PFS in the nicotinamide group was 12.7 months, while it was 10.9 months in the placebo group. The median OS in the nicotinamide group was 31.0 months, while it was 29.4 months in the placebo group.<br /><br />Adverse events, such as skin rash, mucositis, and diarrhea, were similar between the two groups.<br /><br />In conclusion, the study suggests that the addition of nicotinamide to EGFR-TKIs may improve PFS and OS in patients with EGFR-mutated lung adenocarcinoma. Further research is needed to validate these findings and determine the optimal dosage and duration of nicotinamide treatment.

Asset Subtitle

Young-Chul Kim

Meta Tag

Speaker Young-Chul Kim

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

randomized trial

nicotinamide

vitamin B3

EGFR-TKIs

lung adenocarcinoma

EGFR mutations

progression-free survival

overall survival

tumor suppressor gene

adverse events